Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemotuzumab combined with neoadjuvant chemotherapy for TNBC
NCT06975644Not yet recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
01
Overview
Open-label, single-arm trial of bemotuzumab in triple-negative breast cancer (TNBC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Pathological Complete Response at 6 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
bemotuzumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06975644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975644.